Vaxcyte, Inc. (PCVX) is generating significant attention in the biotechnology sector, largely due to its innovative approach to vaccine development and a notable potential upside of 74.52% based on current analyst ratings. As a clinical-stage company, Vaxcyte is at the forefront of developing conjugate and novel protein vaccines aimed at preventing or treating bacterial infectious diseases. The company’s pipeline includes promising candidates such as VAX-24 and VAX-31, which target invasive pneumococcal disease (IPD) in various age groups, and several others focusing on diseases like Group A Streptococcus and periodontitis.

The current market cap for Vaxcyte stands at $8.4 billion, with shares trading at $58.51. This valuation…